Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPopat, Sanjay
dc.contributor.authorBrustugun, Odd Terje
dc.contributor.authorCadranel, Jacques
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorGarassino, Marina Chiara
dc.contributor.authorGriesinger, Frank
dc.date.accessioned2022-03-10T08:40:53Z
dc.date.available2022-03-10T08:40:53Z
dc.date.issued2021-07
dc.identifier.citationPopat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, et al. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 Jul;157:9–16.
dc.identifier.issn0169-5002
dc.identifier.urihttp://hdl.handle.net/11351/7135
dc.descriptionBrigatinib; NSCLC; Tyrosine kinase inhibitor
dc.description.abstractBackground The next-generation ALK inhibitor brigatinib is approved for use in patients with ALK inhibitor-naïve ALK-positive advanced NSCLC and in patients previously treated with crizotinib. A phase II trial showed that brigatinib is active in patients with ALK-positive metastatic NSCLC (mNSCLC) who had progressed on prior crizotinib (response rate 56 %, median PFS 16.7 months, median OS 34.1 months). We report final data from the UVEA-Brig study of brigatinib in ALK inhibitor-pretreated ALK-positive mNSCLC in clinical practice. Methods UVEA-Brig was a retrospective chart review of patients treated with brigatinib in Italy, Norway, Spain and the UK in an expanded access program. Adults with ALK-positive mNSCLC, including those with brain lesions, resistant to or intolerant of ≥1 prior ALK inhibitor and ECOG performance status ≤3 were eligible. Patients received brigatinib 180 mg once daily with a 7-day lead-in at 90 mg. The objectives were to describe patient characteristics, clinical disease presentation, treatment regimens used and clinical outcomes. Results Data for 104 patients (male: 43 %; median age: 53 [29–80] years; ECOG performance status 0/1/2/3: 41/41/10/5 %; brain/CNS metastases: 63 %) were analyzed. Patients had received a median of 2 (1–6) lines of systemic therapy prior to brigatinib (37.5 % received ≥3) and a median of 1 (1–5) lines of prior ALK inhibitor-containing therapy (crizotinib 83.6 %; ceritinib 50.0 %; alectinib 6.7 %; lorlatinib 4.8 %). At the time of analysis, 77 patients had discontinued brigatinib. Overall, the response rate was 39.8 %, median PFS was 11.3 (95 % CI:8.6–12.9) months and median OS was 23.3 (95 % CI: 16.0–NR) months. Four patients discontinued brigatinib treatment due to adverse events. 53 patients received systemic therapy after brigatinib, 42 with an ALK inhibitor (lorlatinib, n = 34). Conclusions These real-world data indicate the activity and tolerability of brigatinib in patients with ALK-positive mNSCLC who were more heavily pretreated than patients included in clinical trials.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesLung Cancer;157
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectPulmons - Càncer - Tractament
dc.subjectMetàstasi
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Outcome
dc.subject.meshNeoplasm Metastasis
dc.titleReal-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.lungcan.2021.05.017
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsresultado del tratamiento
dc.subject.decsmetástasis neoplásica
dc.relation.publishversionhttps://doi.org/10.1016/j.lungcan.2021.05.017
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Popat S] Royal Marsden Hospital and The Institute of Cancer Research, London, UK. [Brustugun OT] Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway. [Cadranel J] Chest Department and Thoracic Oncology, AP-HP Hôpital Tenon and GRC#4 Theranoscan Sorbonne Université Paris, Service de Pneumologie et Oncologie Thoracique, Assistance Publique Hôpitaux de Paris, Paris 75970, France. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Garassino MC] Division of Medical Oncology, Thoracic Oncology Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, 20126 Milan, Italy. The University of Chicago, Department of Medicine Section Hematology/Oncology Knapp Center For Biomedical Discovery, Illinois 60637, USA. [Griesinger F] Department of Hematology and Oncology, University Dept. Internal Medicine-Oncology, Innere Medizin-Onkologie, Koordinator Cancer Center Oldenburg, Pius Hospital, University Medicine Oldenburg, Medizinischer Campus Universität Oldenburg, D-26121 Oldenburg, Germany
dc.identifier.pmid34051652
dc.identifier.wos000658344500002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record